Promising combo therapy shows hope for bile duct cancer patients
NCT ID NCT05052099
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study tested a combination of three drugs (mFOLFOX6, bevacizumab, and atezolizumab) in 20 patients with advanced bile duct cancer who had already tried one prior treatment. The goal was to see if this mix could shrink tumors or control the disease. The drugs were given every two weeks until the cancer worsened, side effects became too severe, or the patient chose to stop.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clínica Universidad de Navarra
Pamplona, 31008, Spain
-
Universitätsklinikum Essen
Essen, North Rhine-Westphalia, 45147, Germany
Conditions
Explore the condition pages connected to this study.